Compare Immunovant Inc. Common Stock (IMVT) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs iShares Core S&P 500 ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while iShares Core S&P 500 ETF trades at $779.84 (market cap $899.63B). The key difference: iShares Core S&P 500 ETF is far larger — about 135.9× Immunovant Inc. Common Stock's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and iShares Core S&P 500 ETF for 46 Days on average.
| IMVT | IVV | |
|---|---|---|
Market Cap | $6.62B | $899.63B |
Volume | 1,131,364 | 3,643,926 |
Sector | Health | Broad Market / Factor |
52-Week High | $44.96 | $782.58 |
52-Week Low | $17.03 | $634.93 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $5.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IVV, tracking the S&P 500, trades at $780.60, down 0.25% on the day. Technical indicators show a bullish trend with moving averages strongly positive, though RSI suggests potential overbought conditions near-term. The ETF remains a core holding for broad US equity exposure, with recent news highlighting strong corporate earnings growth expectations of 35% for 2026. Market sentiment is mixed as valuations attract scrutiny despite index strength.
Outlook remains constructive given the S&P 500's earnings momentum and historical seasonal trends favoring year-end rallies. Key risks include potential profit growth deceleration to 15% in 2027 and concentration in top holdings. The ETF offers diversified exposure to large-cap US equities, with the current level near pivot point support providing a strategic entry zone for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
